|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Interestingly, highly proliferative tumors also demonstrated high MET expression, likely explaining better therapeutic response of MET-high HCC patients to tivantinib.<b>Conclusions:</b> Tivantinib acts as an antimitotic compound, and cell proliferation markers are the best predictors of its antitumor efficacy in cell lines.
|
28246274 |
2017 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
AMG 337 significantly inhibited tumor growth at all doses tested in the MET-amplified and MET-high-expressing hepatocellular carcinoma PDX model LI0612 and had no effect on tumor growth in the non-MET-amplified and MET-low-expressing hepatocellular carcinoma PDX model LI1078.
|
27196749 |
2016 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma.
|
27813498 |
2016 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Treatment of primary cancer cells from patients with HCC expressing both phospho-FGFR and phospho-MET with PHA665752 did not induce cell death, whereas AZD4547 treatment induced cell death through the cleavage of caspase-3.
|
26351320 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tivantinib has been described as a highly selective inhibitor of MET and is currently in a phase III clinical trial for the treatment of hepatocellular carcinoma (HCC).
|
26458953 |
2015 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
IHC analysis of HCC tumors showed significant correlation between c-Met protein expression levels and miR-93 expression levels.
|
25633810 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Furthermore, reports have also indicated that constitutive expression of P-glycoprotein (ABCB1) is involved in the HGF/c-MET-related pathway of multidrug resistance ABCB1-positive human hepatocellular carcinoma cell lines.
|
25908454 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Mounting studies highlighted the essential role of the HGF/c-MET axis in driving HCC tumor progression.
|
25607934 |
2015 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to determine the clinical significance of MET and RON expression on long-term survival and recurrence after curative resection in a large cohort of hepatocellular carcinoma (HCC) patients.
|
25874493 |
2015 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Several pathways have been thought to play a role in the development of HCC; specifically, those involving vascular endothelial growth factor (VEGF)-mediated angiogenesis, WNT, phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and c-MET.
|
26160430 |
2015 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The final purpose is to better clarify which can be the role of MET as a therapeutic target in HCC.
|
24045150 |
2014 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Hypomethylation of long interspersed nuclear element-1 (LINE-1) is associated with poor prognosis via activation of c-MET in hepatocellular carcinoma.
|
24992910 |
2014 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
c-Met receptor tyrosine kinase has been regarded as a promising therapeutic target for hepatocellular carcinoma (HCC).
|
25058462 |
2014 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET.
|
23593387 |
2013 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC.
|
23295441 |
2013 |
|
Liver carcinoma
|
1.000 |
PosttranslationalModification
|
disease |
BEFREE |
Notably, C1GALT1 attenuation also suppressed hepatocyte growth factor (HGF)-mediated phosphorylation of the MET kinase in hepatocellular carcinoma cells, whereas enforced expression of C1GALT1 enhanced MET phosphorylation.
|
23832667 |
2013 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
In addition, c-MET expression levels did not affect RFS or HCC-specific survival. c-MET expression was weakly correlated with c-MET copy number variation (r=0.255, p<0.001), but more than half of all patients with c-MET overexpression had a neutral c-MET copy number. c-MET protein expression was very weakly but significantly positively correlated with its mRNA expression (r=0.199, p=0.002).
|
24222167 |
2013 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
HCC samples from patients had lower levels of miR-449 and higher levels of c-MET than human reference.
|
22641068 |
2012 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We propose that context-specific processing of c-Met protein is implicated in HCC progression in stressful microenvironments.
|
22418436 |
2012 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
However, in our recently published studies, we have documented that AAV3 vectors transduce human liver cancer - hepatoblastoma (HB) and hepatocellular carcinoma (HCC) - cell lines extremely efficiently because AAV3 utilizes human hepatocyte growth factor receptor as a cellular co-receptor for binding and entry in these cells.
|
21445055 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tissue samples were obtained from tumor (TU), adjacent non-tumor (AN) and distant normal (DN) liver in Tet-operator regulated (TRE) human c-MET transgenic mice (n = 21) as well as from a Chinese cohort of 272 HBV- and 9 HCV-associated HCC patients.
|
21949730 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Identification of a malignant stemlike subtype of HCC may offer patients with a dismal prognosis a potential targeted therapy using c-MET and Wnt pathway inhibitors.
|
21737452 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
LHGDN |
Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
|
19065669 |
2009 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
These encode genes, such as EGFR and MET, previously associated with HCC and others, such as UBE2H, that are potential new targets for treating this neoplasm.
|
19234449 |
2009 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
|
19447220 |
2009 |